Polen Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,383
| Closed | -$966K | – | 95 |
|
|
2022
Q1 | $966K | Sell |
1,383
-555
| -29% | -$351K | ﹤0.01% | 82 |
|
|
2021
Q4 | $1.22M | Sell |
1,938
-217
| -10% | -$133K | ﹤0.01% | 81 |
|
|
2021
Q3 | $1.3M | Buy |
+2,155
| New | +$1.34M | ﹤0.01% | 78 |
|
|
2021
Q1 | – | Sell |
-2,002,804
| Closed | -$968M | – | 76 |
|
|
2020
Q4 | $968M | Buy |
2,002,804
+65,147
| +3% | +$35.2M | 2.25% | 20 |
|
|
2020
Q3 | $1.08B | Buy |
1,937,657
+93,123
| +5% | +$56.5M | 2.9% | 16 |
|
|
2020
Q2 | $1.15B | Buy |
1,844,534
+123,532
| +7% | +$70.1M | 3.48% | 14 |
|
|
2020
Q1 | $840M | Buy |
1,721,002
+44,708
| +3% | +$18.4M | 3.65% | 12 |
|
|
2019
Q4 | $629M | Buy |
1,676,294
+34,084
| +2% | +$11.5M | 2.48% | 18 |
|
|
2019
Q3 | $456M | Buy |
1,642,210
+57,097
| +4% | +$16.9M | 2.1% | 20 |
|
|
2019
Q2 | $496M | Sell |
1,585,113
-17,448
| -1% | -$5.81M | 2.41% | 18 |
|
|
2019
Q1 | $658M | Buy |
1,602,561
+117,306
| +8% | +$48.3M | 3.44% | 17 |
|
|
2018
Q4 | $555M | Sell |
1,485,255
-3,237
| -0.2% | -$1.18M | 3.62% | 15 |
|
|
2018
Q3 | $601M | Buy |
1,488,492
+4,858
| +0.3% | +$1.85M | 3.42% | 17 |
|
|
2018
Q2 | $512M | Buy |
1,483,634
+64,493
| +5% | +$20.2M | 3.29% | 16 |
|
|
2018
Q1 | $489M | Buy |
1,419,141
+29,596
| +2% | +$10.3M | 3.47% | 16 |
|
|
2017
Q4 | $522M | Buy |
1,389,545
+15,931
| +1% | +$6.45M | 3.88% | 15 |
|
|
2017
Q3 | $614M | Sell |
1,373,614
-212,706
| -13% | -$101M | 4.94% | 12 |
|
|
2017
Q2 | $779M | Buy |
1,586,320
+108,413
| +7% | +$47.4M | 6.81% | 5 |
|
|
2017
Q1 | $573M | Buy |
1,477,907
+137,258
| +10% | +$50.9M | 5.33% | 9 |
|
|
2016
Q4 | $492M | Buy |
1,340,649
+529,348
| +65% | +$201M | 5.42% | 8 |
|
|
2016
Q3 | $326M | Buy |
811,301
+23,431
| +3% | +$9.4M | 3.89% | 17 |
|
|
2016
Q2 | $275M | Buy |
787,870
+81,780
| +12% | +$31.5M | 3.49% | 19 |
|
|
2016
Q1 | $255M | Buy |
706,090
+80,393
| +13% | +$33.1M | 3.49% | 18 |
|
|
2015
Q4 | $340M | Buy |
625,697
+50,192
| +9% | +$27.2M | 5.25% | 6 |
|
|
2015
Q3 | $268M | Buy |
575,505
+20,546
| +4% | +$11M | 4.91% | 8 |
|
|
2015
Q2 | $283M | Sell |
554,959
-11,906
| -2% | -$5.81M | 5.48% | 6 |
|
|
2015
Q1 | $256M | Buy |
566,865
+24,572
| +5% | +$10.4M | 4.99% | 10 |
|
|
2014
Q4 | $222M | Sell |
542,293
-9,609
| -2% | -$3.78M | 4.58% | 12 |
|
|
2014
Q3 | $199M | Buy |
551,902
+343,312
| +165% | +$115M | 4.47% | 11 |
|
|
2014
Q2 | $58.9M | Sell |
208,590
-10,573
| -5% | -$3.13M | 1.29% | 21 |
|
|
2014
Q1 | $65.8M | Buy |
219,163
+217,412
| +12,416% | +$67M | 1.42% | 20 |
|
|
2013
Q4 | $482K | Hold |
1,751
| – | – | 0.01% | 22 |
|
|
2013
Q3 | $548K | Hold |
1,751
| – | – | 0.01% | 22 |
|
|
2013
Q2 | $394K | Buy |
+1,751
| New | +$408K | 0.01% | 24 |
|
Other funds holding REGN
Polen Capital Management's REGN Position: Q2 2022 in Review
Polen Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 1,383 shares — an estimated $966K sold.
Polen Capital Management first reported a position in REGN in Q2 2013 and held it in 34 quarters. The position peaked at $1.15B in Q2 2020. 1,063 funds tracked by Wall St. Rank hold REGN as of Q2 2022.
- Polen Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
- Polen Capital Management sold 1,383 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $966K.
- Polen Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 34 quarters.
- Polen Capital Management's Regeneron Pharmaceuticals position peaked at $1.15B in Q2 2020.
- 1,063 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.
Based on Polen Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.